You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Expanded Access

Showing 1 - 25 of 8,833
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDD, Depression Trial (REL-1017)

Available
  • Major Depressive Disorder
  • Depression
  • (no location specified)
Aug 17, 2023

SCA, Spinocerebellar Ataxias Trial (Troriluzole)

Available
  • SCA
  • Spinocerebellar Ataxias
  • (no location specified)
Sep 6, 2023

NSCLC Trial (ABBV-400)

Available
  • Non-Small Cell Lung Cancer
  • (no location specified)
Aug 1, 2023

Lafora Disease Trial (VAL-1221)

Available
  • Lafora Disease
  • (no location specified)
Jun 25, 2023

Colitis, Ulcerative Trial (Etrasimod)

Available
  • Colitis, Ulcerative
  • (no location specified)
Aug 29, 2023

Expanded Access Trial (RBS2418)

Available
  • Expanded Access
  • (no location specified)
Dec 26, 2022

COVID-19 Trial (VYD222)

No longer available
  • COVID-19
  • (no location specified)
Aug 18, 2023

Alzheimer Trial (TB006)

Available
  • Alzheimer Disease
  • (no location specified)
Jul 14, 2023

Lymphoma Trial (Epcoritamab)

Available
  • Lymphoma
  • (no location specified)
Jan 13, 2023

Relapsed/Refractory Acute Leukemia Trial (SNDX-5613)

Available
  • Relapsed/Refractory Acute Leukemia
  • (no location specified)
Jun 15, 2023

Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, With NPM1 Mutations Trial (ziftomenib)

Available
  • Acute Lymphoblastic Leukemia, With Appropriate Mutations
  • Acute Myeloid Leukemia, With NPM1 Mutations
  • (no location specified)
Feb 10, 2023

Trial (Repotrectinib)

Available
    • (no location specified)
    Jun 30, 2023

    Trial (Cemiplimab)

    Available
      • (no location specified)
      Nov 9, 2023

      Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

      Available
      • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
      • Relapsed/Refractory Acute Myeloid Leukemia
      • Magrolimab
      • (no location specified)
      Jan 18, 2023

      Metastatic Castration-Resistant Prostate Cancer Trial (Talazoparib)

      Available
      • Metastatic Castration-Resistant Prostate Cancer
      • (no location specified)
      Dec 6, 2022

      Graft-versus-host Disease (GVHD) Trial (Ruxolitinib)

      Approved for marketing
      • Graft-versus-host Disease (GVHD)
      • (no location specified)
      Jan 26, 2023

      Hypoparathyroidism Trial (Palopegteriparatide (TransCon PTH))

      Available
      • Hypoparathyroidism
      • Palopegteriparatide (TransCon PTH)
      • (no location specified)
      Jan 10, 2023

      Small Cell Lung Cancer Trial (Tarlatamab)

      Available
      • Small Cell Lung Cancer
      • (no location specified)
      Sep 26, 2023

      MDS Trial (Imetelstat)

      Available
      • Myelodysplastic Syndromes
      • (no location specified)
      Jun 30, 2023

      Thrombotic Thrombocytopenic Purpura (TTP) Trial (TAK-755)

      No longer available
      • Thrombotic Thrombocytopenic Purpura (TTP)
      • (no location specified)
      Mar 3, 2023

      Dravet Syndrome Trial (Fenfluramine Hydrochloride)

      Approved for marketing
      • Dravet Syndrome
      • Fenfluramine Hydrochloride
      • (no location specified)
      Nov 8, 2022

      Parkinson Disease Trial (HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells))

      Available
      • Parkinson Disease
      • HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)
      • (no location specified)
      Sep 20, 2023

      Low-grade Glioma Trial (Tovorafenib)

      Available
      • Low-grade Glioma
      • (no location specified)
      Feb 23, 2023

      Recurrent Glioblastoma Trial in Portland (TVI-Brain 1)

      Available
      • Recurrent Glioblastoma
      • TVI-Brain 1
      • Portland, Oregon
        Providence St. Vincent Medical Center
      Jun 28, 2023

      Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)

      Available
      • Clear Cell Renal Cell Carcinoma
      • 89Zr-DFO-girentuximab
      • Los Angeles, California
        UCLA
      Oct 12, 2023